Arcutis Biotherapeutics, Inc. (ARQT) research
Arcutis Biotherapeutics, Inc.- Sector
- Biotechnology
- Last price
- $25.15
- As of
Kresmion compiles this page from ARQT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Arcutis Biotherapeutics, Inc. (ARQT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for ARQT. Method and limitations.
Share the ARQT intelligence card
See the full ARQT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ARQT on one page. Preview it with sample data, then open it live with a free account.
Preview the ARQT dossierActive signals for ARQT
- highCONSENSUS_BUY
5 tracked funds increased ARQT this 2026Q2, institutional consensus
- lowEARNINGS_BEAT
Q2-2026: EPS $0.11 vs $0.0439 estimate, +0.07 on a near-zero consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 59% of ARQT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +179% to ARQT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3322% to ARQT (2026Q2)
FREE, NO ACCOUNT
Every signal on ARQT, as it fires
You are seeing 5 of 16 signals recorded on ARQT since 2026-06-10.
The five above landed across 2 days. The other 11 were recorded on 2 other days. 9 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARQT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 03969K108 · 2026Q2 | $103.6M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 03969K108 · 2026Q2 | $30.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03969K108 · 2026Q2 | $17.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03969K108 · 2026Q2 | $14.8M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 03969K108 · 2026Q2 | $9.5M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03969K108 · 2026Q2 | $1.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARQT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARQT against its peers
ARQT's operating margin of -3.3% ranks in the 72nd percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ARQT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 376M USD | 33.0M USD | 64 | 17 |
| Operating margin | -3.3% | -178.4% | 72 | 15 |
| Net margin | -4.3% | -162.9% | 72 | 15 |
| Return on equity | -8.5% | -29.8% | 77 | 23 |
Peers (23): ACAD, GRTX, ELVN, DNLI, XENE, RCUS, IDYA, VCYT, CPRX, DYN, RLAY, CELC, LEGN, TLX, ZLAB, TNGX, VKTX, NAMS, PGEN, MBX, EWTX, ATAI, QURE. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ARQT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ARQT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ARQT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.